Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors
Adrienne G. Waks(Harvard University), Lindsey R. Baden(Brigham and Women's Hospital), Alicia Galar(Brigham and Women's Hospital), Sarah P. Hammond(Dana-Farber Cancer Institute), Julie Porter(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Eric P. Winer(University of Vermont), Amal Arnaout(Dana-Farber Cancer Institute), Francisco M. Marty(Brigham and Women's Hospital)
Cited by 43
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k